

DR. LOREEN THÜRMANN (Orcid ID : 0000-0003-1109-1924)

PROF. IRINA LEHMANN (Orcid ID : 0000-0001-8875-5587)

Article type : Original Article: Atopic Dermatitis, Urticaria and Skin Disease

Prenatal paraben exposure and atopic dermatitis-related outcomes among children

Manuscript Acceptance Date: 13-Apr-2021

Loreen Thürmann, PhD^{a†}, Gunda Herberth, PhD^{b†}, Bettina Seiwert, PhD^{c†}, Linda Schlittenbauer, PhD^c, Ulrike Rolle-Kampczyk, PhD^d, Stefan Röder, PhD^b, Ulrich Sack, MD^e, Michael Borte, MD^f, Martin von Bergen, PhD^{d,g}, Saskia Trump, PhD^{a†}, Thorsten Reemtsma, PhD^{c†}, Irina Lehmann, PhD^{a*†}

^a Molecular Epidemiology Unit, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, associated partner of the German Center for Lung Research (DZL), Berlin, Germany

^b Department of Environmental Immunology, Helmholtz Centre for Environmental Research-UFZ, Leipzig, Germany

^c Department of Analytical Chemistry, Helmholtz Centre for Environmental Research – UFZ, Leipzig, Germany

^d Department of Molecular Systems Biology, Helmholtz-Centre for Environmental Research-UFZ, Leipzig, Germany

^e Institute of Clinical Immunology, Medical Faculty, University Leipzig, Leipzig, Germany

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the [Version of Record](#). Please cite this article as [doi: 10.1111/ALL.14890](https://doi.org/10.1111/ALL.14890)

This article is protected by copyright. All rights reserved

^f Children's Hospital, Municipal Hospital "St.Georg", Academic Teaching Hospital of the University of Leipzig, Leipzig, Germany

^g Department of Biochemistry, Faculty of Biosciences, Pharmacy and Psychology, University of Leipzig, Leipzig, Germany

[†] equal contribution

***Corresponding author:**

Prof. Dr. Irina Lehmann, Molecular Epidemiology Unit, Charité - Universitätsmedizin Berlin and Berlin Institute of Health, Kapelle-Ufer 2, 10117 Berlin, Phone: +4930-450-543094, Fax: +4930-450-7-576902, mail: irina.lehmann@charite.de

Short title: Prenatal paraben exposure & childhood atopic dermatitis

Keywords: allergy, atopic dermatitis, paraben, prenatal, sex

Acknowledgment

We cordially thank all participants of the LINA study and are grateful to Melanie Bansch and André Andrecke for their excellent assistance and fieldwork. This work was supported by institutional funding from the Helmholtz Centre for Environmental Research – UFZ in Leipzig, Germany, and the Berlin Institute of Health, Berlin, Germany.

Conflict of interest:

The authors have no conflict of interest to declare.

Abstract

Background: Parabens, widely used as preservatives in cosmetics, foods, and other consumer products, are suspected of contributing to allergy susceptibility. The detection of parabens in the placenta or amniotic fluid raised concerns about potential health consequences for the child. Recently, an increased asthma risk following prenatal exposure has been reported. Here we investigated whether prenatal paraben exposure can influence the risk for atopic dermatitis (AD).

Methods: 261 mother-child-pairs of the German mother-child-study LINA were included in this analysis. Eight paraben species were quantified in maternal urine obtained at gestational week 34. According to the parental report of physician-diagnosed AD from age one to eight years, disease onset, and persistence, childhood AD was classified into four different phenotypes.

Results: 4.6% (n=12) and 12.3% (n=32) of the children were classified as having very early-onset AD (until age two) either with or without remission, 11.9% (n=31) as early-onset (after age two), and 3.1% (n=8) as childhood-onset AD (after age six). Exposure to ethylparaben and *n*-butylparaben was associated with an increased risk to develop very early-onset AD without remission (EtP: adj. OR/95% CI: 1.44/1.04-2.00, nBuP: adj. OR/95% CI: 1.95/1.22-3.12). The effects of both parabens were predominant in children without a history of maternal AD and independent of children's sex.

Conclusion: Prenatal EtP or nBuP exposure may increase children's susceptibility for persistent AD with disease onset at very early age. This association was particularly pronounced in children without a history of maternal AD, indicating that children without a genetic predisposition are more susceptible to paraben exposure.

Abbreviations:

AD	atopicdermatitis
CHAMACOS	The Center for the Health Assessment of Mothers and Children of Salinas
CI	confidence interval
CoRAP	Community rolling action plan
ECHA	European Chemicals Agency
EDC	endocrine-disrupting chemicals
EDEN	Etude des Determinants pre et post natal du developpement et de la sante de l'Enfant
IQR	interquartile range
LINA	Lifestyle and Environmental Factors and their Influence on Newborns Allergy risk
LOQ	limit of quantification
Me-/Et-/iPr-/nPr-/nBu-/iBu-/sBu/BzP	methyl-, ethyl-,isopropyl-, <i>n</i> -propyl-, isobutyl-, <i>n</i> -butyl-, <i>sec</i> -butyl-,benzylparaben
NHANES	US National Health and Nutrition Examination Surveys
OR	odds ratio
UPLC	Ultra Performance Liquid Chromatography

1. Introduction

Parabens are preservatives widely used in cosmetics, pharmaceuticals, and food products due to their antimicrobial properties^{1,2}. As a result of the extensive usage, parabens are now omnipresent in the environment^{3,4} and numerous studies confirmed a ubiquitous presence of parabens among various body fluids and tissues⁵⁻⁸. Parabens are classified as endocrine-disrupting chemicals (EDCs) shown to bind to the estrogen receptor⁹. In line, exposure to parabens has been linked to reproductive malfunctions¹⁰, while also obesogenic effects have been described^{11,12}. Due to the immunomodulatory capacity¹³ and the antimicrobial activity of parabens¹⁴ probably affecting the microbiome¹⁵, it has been speculated that the extensive usage of paraben-containing consumer products could have contributed to the increased prevalence of allergic diseases observed in the last decades¹⁶.

The first pieces of evidence that parabens might increase the risk for pediatric allergic diseases came from cross-sectional studies. In NHANES (US National Health and Nutrition Examination Surveys) a positive association of urinary parabens to aeroallergen sensitization^{17,18} and asthma-related emergency department visits¹⁹ has been identified in children aged between six and 19 years with a more pronounced effect among boys. In the same survey, no association was found between urinary paraben concentration and atopic dermatitis (AD) frequency or asthma diagnosis in six to 18-years-old children¹⁸. On the contrary, increased urinary paraben concentrations were observed in Japanese adolescents with current AD and in trend also with wheezing symptoms²⁰.

Since there are even substantial paraben concentrations measurable in the placenta, cord blood, or amniotic fluid²¹, concerns about potential adverse health consequences following a paraben exposure during early development arose. To date, the contribution of a prenatal paraben exposure on allergic diseases in particular to atopic dermatitis is largely unexplored, and results of the limited number of studies are inconsistent. The three previous studies mainly focused on asthma/wheeze and IgE sensitization as an allergic outcome²²⁻²⁴. In the two independent US studies, no positive association was observed between a prenatal MeP, PrP, or BuP exposure and allergic sensitization or asthma/wheezing among three-²² or seven-year-old children²⁴. In the French EDEN (Etude des Determinants pre et post natus du developpement et de la sante de l'Enfant) mother-child study a weak association of prenatal EtP exposure to asthma was observed in five-year-old boys, while no association for BuP or PrP was identified with wheezing, bronchitis or

asthma until the age of five²³. Only the US CHAMACOS (The Center for the Health Assessment of Mothers and Children of Salinas) study included AD present at the age of seven years (current AD) in the examination of effects related to prenatal paraben exposure and allergic diseases and identified no association²⁴. However, one recent study showed that the presence of BuP in breast milk is associated with AD at the age of one year²⁵. As such, more research is needed to explore the prenatal effects of parabens on AD at earlier ages.

AD is regarded as the first manifestation of allergies and a disease onset at a very early age is a major risk factor for the progression in the atopic march²⁶. This highly heterogeneous, chronic inflammatory skin disease has a multifactorial etiology and a peak age of disease onset before two years of life. Therefore, for a valid evaluation of a potential contribution of prenatal paraben exposure on AD risk in childhood, considering AD subtypes based on the disease onset, is warranted.

To address this knowledge gap, the current study aimed to examine whether prenatal paraben exposure was associated with an increased risk for children to develop AD up to the age of eight years with a particular focus on specific AD subtypes. Using samples and data from the longitudinal prospective mother-child cohort LINA (Lifestyle and Environmental Factors and their Influence on Newborns Allergy risk), the potential association between maternal urine paraben concentrations and children's AD risk was studied. Measurements of eight parabens were available. We focused on those five parabens, namely methylparaben (MeP), ethylparaben (EtP), propylparaben (PrP), isobutylparaben (iBuP), and *n*-butylparaben (nBuP), which showed concentrations above the lowest limit of quantification in over 70% of the maternal urine samples.

2. Methods

2.1. Study design

This study is based on a subcohort of 261 children of the prospective mother-child cohort LINA for whom longitudinal AD information and relevant covariate data until the age of eight years as well as maternal paraben urine measurements at the 34th week of pregnancy were available (Figure 1).

In LINA, 629 mother-child pairs were recruited from March 2006 until December 2008 in Leipzig, Germany. Standardized questionnaires (self-administered by the parents) on family history of atopy, housing/environmental conditions, and atopic outcomes of the children were recorded during pregnancy and annually thereafter. Participation in the study was voluntary and written informed consent was given by the parents. The LINA study was approved by the Institutional Review Board of the University of Leipzig and the Saxonian Board of Physicians (046-2006, 160-2008, 160b/2008, 144-10-31052010, 113-11-18042011, 206-12-02072012, 169/13-ff, 150/14-ff, EK-allg-28/14-1).

2.2. Paraben measurement

Urinary concentrations of eight paraben species namely methylparaben (MeP), ethylparaben (EtP), isopropylparaben (iPrP), *n*-propylparaben (nPrP), *sec*-butylparaben (sBuP), isobutylparaben (iBuP), *n*-butylparaben (nBuP), and benzylparaben (BzP) were determined in maternal urine samples of the 34th week of gestation as previously described using a UPLCTM system (ACQUITY I-Class, Waters Cooperation Milford, MA, USA) coupled to a triple quadrupole mass spectrometer (Xevo TQ-S, Waters Cooperation, Manchester, UK) and equipped with an electrospray ionization (ESI) source²⁷. For MeP, the limit of quantification (LOQ) was 0.5 µg/l and 0.1 µg/l for the other parabens (EtP, iPrP, nPrP, sBuP, iBuP, nBuP, BzP). For iPrP, sBuP, and BzP more than 80% of samples had concentrations below the LOQ and were therefore excluded from further analyses (Table S1). For the remaining parabens, concentrations below LOQ were assigned a value that was half of the LOQ.

2.3. IgE measurement

Concentrations of total serum IgE were determined by the Pharmacia CAP System (Pharmacia Diagnostics, Freiburg, Germany).

2.4. Dependent variable: atopic dermatitis classification

Information on physician-diagnosed AD manifestation until the age of eight years was obtained annually from questionnaires: “Has a physician-diagnosed your child with allergic or atopic dermatitis/eczema or neurodermatitis in the past year?”. The classification of AD subtypes was based on the age of disease onset as proposed by Bieber *et al.*²⁸. To this end, the children were classified in either (1) “very early-onset AD without remission” (AD in the first two years and onset at least once after the age of two), (2) “very early-onset AD with remission” (AD diagnosis exclusively in the first two years and no AD manifestation after the age of two), (3) “early-onset AD” (first AD diagnosis after the age of two and until the age of six), or (4) “childhood-onset AD” (first AD diagnosis after the age of six). Controls were never diagnosed with AD until the age of eight years (Figure 1).

Maternal AD was defined according to the question “Did you ever suffer from atopic dermatitis/eczema?” included in the pregnancy questionnaire. Accordingly, the maternal control group for AD did not report AD.

2.5. Independent variables: covariates

To control for potential confounding factors, we *a priori* tested for associations between all AD subtypes and environmental and genetic factors, which have previously been associated with childhood AD, by applying crude binary logistic regressions. These factors included prenatal exposure and life style factors such as parental education level, renovation activities during pregnancy²⁹, prenatal tobacco smoke exposure³⁰, cat ownership³¹, as well as genetic influences like the child’s sex, and the maternal history of AD³². Maternal AD, which was shown to be the strongest risk factor for early AD in the LINA study³³, was used to account for a genetic predisposition. Whenever one factor was significantly associated with any AD subtype, it was considered as a covariate.

Following this approach, we retained prenatal tobacco smoke exposure, renovation activities during pregnancy, the child’s sex, and the maternal history of AD as influencing factors for AD. As illustrated by the directed acyclic graph (Figure 2) the parental education level was not directly associated with AD and therefore not included in downstream analyses. However, smoking and renovation activities during pregnancy were associated with the parental education level.

Information on covariates was derived from questionnaires, except for prenatal tobacco smoke exposure, where the ln-transformed maternal urinary cotinine concentration at the 34th gestational week was used ³⁴.

To adjust urinary paraben concentrations for creatinine we included ln-transformed creatinine concentrations measured at the 34th week of pregnancy as an independent variable in any statistical model³⁵.

2.6. Statistics

Chi-squared and Mann-Whitney U tests were used to test for equal parameter distribution and paraben concentrations between the analyzed subcohort and the entire LINA cohort.

To elucidate the potential contribution of a maternal history of AD on the relationship between prenatal EtP or nBuP exposure and the development of childhood AD a moderation model was conducted using Andrew Hayes' process macro (process macro v3.4 for SPSS³⁶, www.processmacro.org) with a bootstrap approach of 5,000 samples to estimate the statistical significance of the moderating effect as bias-corrected 95% CIs. In this model, EtP and nBuP exposure were dichotomized, where high was defined as an exposure above and low exposures below the geometric mean. The moderation analyses were adjusted using the covariates described above.

To test for a potential association of prenatal paraben exposure and the different AD subtypes multinomial logistic regression models were applied. Since paraben concentrations are highly correlated (Table S2), models were conducted for each paraben separately to exclude multicollinearity. Models were adjusted for covariates selected as described above and paraben concentrations were z-score transformed to allow for better comparability of the effect size between the different parabens. The association of EtP and nBuP on very-early onset AD in different subgroups of the study cohort was assessed by adjusted binary logistic regression. Linearity in our logistic regression models was tested by the Box-Tidwell procedure.

Continuous variables were either z-score- or ln-transformed before analyses. As we investigated *a priori* hypotheses no multiple test correction was performed ³⁷. *P*-values ≤ 0.05 were considered significant. Analyses were performed in either STATISTICA 13.3 for Windows (Dell Inc., USA), GraphPad Prism version 7.00 for Windows (GraphPad Software, USA), or IBM SPSS Statistics version 25 (IBM Corps., USA).

3. Results

3.1. Study characteristics

For this explorative study, longitudinal data on the onset of AD was used to classify the different AD phenotypes according to Bieber *et al.*²⁸ (Figure 1A). Only children with valid maternal paraben measurements at the 34th week of pregnancy and with information on longitudinal AD manifestation and confounding factors up to the age of eight were included. To this end, 261 children were considered in subsequent analyses (Figure 1B). There was no general selection bias in the analyzed subcohort compared to the whole LINA cohort, except a minor difference in parental education level with a tendency that higher educated parents continued to participate in the eight-year follow-up study of LINA (Table 1).

The maternal urinary paraben concentrations differed among the analyzed species. MeP (median (IQR)= 38.2 µg/l (10.8-147.0), nPrP= 4.6 µg/l (1.0-21.5)) were most abundant, followed by EtP (median (IQR)=2.5 µg/l (0.8-11.5)) and the two BuP derivatives (median (IQR): iBuP= 0.2 µg/l (0.1-0.75), nBuP= 0.7 µg/l (0.2-2.7), Table 1, Table S1).

Until the age of eight years, 68.2% (n=178) of the children were never diagnosed with AD. The children, who ever developed AD, were stratified based on their age of disease onset as proposed by Bieber *et al.*²⁸. The majority of the children with AD developed first symptoms within the first two years of life and were classified as very early-onset AD, either with (n=12, 4.6%), or without remission (n=32, 12.3%). 11.9% of the children (n=31) developed AD after the age of two, but before the age of seven (early-onset AD), whereas only a minor part was diagnosed after the age of six and was subsequently classified as childhood-onset AD (n=8, 3.1%, Figure 1B).

3.2. Prenatal paraben exposure and AD manifestation during childhood

To elucidate the contribution of a prenatal paraben exposure on the children's risk to develop different types of AD, multinomial logistic regression models adjusted for AD covariates were applied (Figure 2, Table 2, Table S3). Z-scores were used in this regression analysis so odds ratios correspond to a one unit change in the SD of the paraben concentration. Increased urinary gestational EtP and nBuP concentrations were associated with an increased risk for the children to develop very early-onset AD without remission (EtP: adj. OR/95% CI: 1.44/1.04-2.00), p -value=0.029; nBuP: adj. OR/95% CI: 1.95 (1.22-3.12), p -value=0.005, $n=32$ vs. 178, Table 2, Figure 3), but not with the other AD subtypes. Only children with this very early and persistent AD subtype showed elevated longitudinal serum IgE concentrations from age one onwards compared to controls (Figure S1).

3.3. Influence of a maternal history of AD and child's sex

Besides prenatal EtP and nBuP exposure, a significant association to very early-onset AD without remission was also observed for renovation activities during pregnancy, prenatal tobacco smoke exposure, and maternal AD, with the latter being the major risk factor with the highest OR (OR/95% CI: 3.08/1.35-7.02, p -value=0.007, $n=32$ vs. 178, Table 2B). Note that the paternal history of AD was not associated with very early-onset AD without remission (OR/95% CI: 1.78/0.54-5.90, p -value=0.344).

Separating the children in those with and those without a history of maternal AD, the influence of prenatal EtP or nBuP was apparent in children without a history of maternal AD (EtP: adj. OR/95% CI=1.43/1.09-1.89, nBuP: adj. OR/95% CI=1.37/1.06-1.78), while in children with a maternal predisposition, the effect of EtP or nBuP was less pronounced (EtP: adj. OR/95% CI=1.05/0.70-1.57, nBuP: adj. OR/95% CI=1.07/0.69-1.64; Figure S2, Table S4).

Subsequently, to elucidate whether a maternal history of AD indeed influences the effect of a prenatal EtP or nBuP exposure and the risk for very early-onset AD without remission, we implemented a moderation model considering both parabens as a binary variable. In contrast to mediators directly associated with the independent variable (paraben exposure), a moderator modifies the strength or direction of the relationship between the independent and dependent (childhood AD) variable without being causally affected by the independent variable.

In the moderation model a significant interaction term was found for maternal history of AD and EtP or nBuP (EtP: β (95% CI)=-2.10(-3.91/-0.29), p -value=0.023; nBuP: β (95% CI)=-1.68 (-3.47/

-0.10), p -value=0.065, Table 3A-B, Figure 4), suggesting that the effect of a prenatal EtPnBuP exposure on very early-onset AD without remission is different in children without a maternal predisposition and those who had a mother suffering from AD. Since EtP or nBuP exposure was positively related to very early-onset AD without remission solely in children without a maternal history of AD (EtP: β (95% CI)=1.03(0.02/2.05), p -value=0.045; nBuP: β (95% CI)=1.19(0.14/2.24), p -value=0.027), but not in children with a maternal history of AD (EtP: β (95% CI)=-1.07(-2.56/0.43), p -value=0.163, nBuP, β (95% CI)=-0.49(-1.98/0.99), p -value=0.514, Table 3), a prenatal paraben exposure seems to be associated with AD dominantly in children not being genetically predisposed. Note that for none of the other parabens a moderating effect by the maternal history of AD was observed (data not shown).

When we studied the influence of a prenatal paraben exposure on very early-onset AD without remission, we did not see a significant impact of the child's sex on this AD phenotype (Table 2B). In agreement, neither for EtPnBuP (Table S5 and S6) nor for any other paraben species (data not shown) a moderating effect by child's sex was observed.

4. Discussion

The prevalence of childhood AD has steadily increased and this observation is attributed to changing environmental influences³⁸. The current study provides evidence for a contribution of prenatal exposure to different parabens, namely EtP and nBuP, to the risk of developing very early-onset AD without remission, which is the most prevalent form of AD in the general population, and relevant for the atopic march²⁸. This agrees with our observation that 39% of the AD children in our study suffered from this persistent AD subtype and that those children showed the highest total serum IgE concentrations longitudinally.

Among the five parabens investigated (MeP, EtP, nPrP, iBuP, nBuP), prenatal exposure to EtP and nBuP were associated with an increased risk to develop the persistent AD phenotype already manifested before the age of two years. This association was predominant in children without a history of maternal AD indicating that children who are not genetically predisposed might be more susceptible to paraben exposure. No association was observed to any other AD subtype developed later in life. These results agree with the US CHAMACOS study, in which urinary MeP, PrP, and BuP was analyzed, and which did not observe an association of a prenatal paraben exposure to AD at the age of seven years²⁴.

In the NHANES national study, which investigated the influence of different EDCs among 6-18 years old children on allergic outcomes, an association with aeroallergen sensitization was observed only for EDCs with antimicrobial activity, such as parabens, but not for EDCs without an antimicrobial capacity¹⁷. This observation might provide some evidence that in terms of allergies, the antimicrobial properties rather than the role as an EDC might be crucial for the association seen between paraben exposure and allergic outcomes.

During the prenatal period, the penetration of antimicrobial active compounds like parabens across the placenta and accumulation in breast milk might influence the composition of the maternal microbiome as well as the developing microbiome of the infant known to be crucial for atopic manifestations³⁹. Transplacental passage of BuP⁴⁰, accumulation of maternal EtP and BuP in amniotic fluid as previously seen in rats⁴¹ as well as the presence of EtP and BuP in breast milk⁴²⁻⁴⁵ may increase the exposure burden of the fetus and prolong the exposure time to the perinatal phase⁴⁶. In an explorative study, high concentrations of BuP in breast milk were associated with AD in one-year-old children²⁵. Although the study was unable to detect EtP in breast milk

samples, it supports the general notion that parabens might be involved in the early pathophysiology of AD.

Besides a potential impact on the microbiome, parabens might play an additional role in AD pathophysiology. This idea is supported by an *in vitro* study demonstrating that MeP affects keratinocyte differentiation following long-term exposure⁴⁷. Thus, parabens might also have the potential to directly perturb skin development. In addition, low amounts of IL-1 β in breast milk have been associated with an increased risk of early AD⁴⁸. Since EtP was shown to be associated with reduced IL-1 β in pregnant women⁴⁹, a perturbation in maternal immune signaling by EtP might contribute to the child's increased AD risk.

Although BuP is thought to have a stronger estrogenic activity than EtP^{50,51}, for both parabens the association to very early-onset AD was not dependent on the child's sex. This contrasts with previous studies, which have implied sex-dimorphic effects following paraben exposure in relation to allergic outcomes^{17,19,22}. Since uterotrophic effects were observed for EtP in a rat model together with the upregulation of estrogen-responsive genes⁵² and BuP is considered an endocrine disrupter⁵³, it cannot be excluded that also early EtP or nBuP exposure might induce sex-dimorphic effects in the context of other diseases than AD.

This study has to be seen in the light of some limitations. Paraben measurements have been performed at only one time-point during late gestation and might therefore not represent the overall exposure. However, we previously confirmed in our LINA study that the usage of paraben-containing leave-on cosmetics by the mother during the entire pregnancy period coincided with high paraben urine concentrations at this single time-point measurement¹¹. This result suggests that a one-time spot-urine measurement could be a valid surrogate for an overall paraben exposure.

The diagnosis of AD cases is based on parent-reported questionnaires, which might introduce misclassifications. However, the longitudinal study design including eight-year follow-up data increased the validity of the applied classification, which is supported by the observed prevalence of the AD subtypes being in agreement with the distribution in the general population according to Bieber *et al.*²⁸. In this study, only eight children (9.6% of the AD children) showed AD symptoms after the age of seven. As such, results regarding this subtype need to be interpreted with caution.

Childhood-onset AD represents an AD subtype, which is not well investigated, probably because only ~10% of the AD children develop this rare AD form²⁸. Therefore, large population-based studies including school-aged children are needed to evaluate the effect of a prenatal paraben exposure on childhood-onset AD. Due to the nature of explorative epidemiological studies,

causality cannot be derived and future studies are needed to confirm the results of the current study, and to elucidate potential molecular mechanisms, e.g. whether indeed a perturbed microbiome is involved in the observed effects of parabens.

The longitudinal design and the availability of maternal urine samples together with eight-year follow-up data on children's health outcomes is the major strength of this study.

Taken together, we here show for the first time an association between prenatal EtP and BuP exposure and the development of very early-onset AD without remission. This persistent type of AD manifestation is considered the most severe AD phenotype and those children suffering from AD at this very early age are at high risk for the progression into the atopic march^{26,54}. Lowering risk factors such as paraben exposure in the developmental period might therefore not only attenuate the risk for very early-onset AD but even reduce the likelihood of other atopic manifestations.

There is an ongoing debate about the safety of parabens used in consumer products in particular for cosmetics. To date, the EU already banned five parabens in cosmetic products and lowered the concentration limits for the use of the remaining parabens. EtP is considered safe in the maximum concentration of 0.4% and as a non-potent allergen⁵⁵. Contradictory, EtP is currently on the European ECHA CoRAP (Community rolling action plan), which identifies EtP⁵⁶ as a high-priority chemical for evaluation due to concerns regarding potential environmental and health consequences. Denmark has banned BuP in cosmetic products for children younger than three years of age⁵⁷. Although the 2013 SCCS report considered BuP as a safe preservative in cosmetic products for adults and children⁵⁷, the ECHA added BuP to their list of substances of very high concern⁵³. Based on the current stage of risk assessment, further epidemiological studies evaluating the effects of prenatal paraben exposure and the consequences for the immune system are highly warranted to provide valid data for safety recommendations. However, although more studies and subsequent risk assessments are necessary regarding the usage of parabens, precautionary approaches are advisable when dealing with paraben-containing consumer products. As we and others have demonstrated that high urinary paraben concentration are associated with cosmetic usage^{11,42}, one strategy might be the avoidance of paraben-containing leave-on products during critical developmental time windows.

Table 1: Characteristics of the entire LINA cohort and the investigated subcohort.

	entire cohort n=629 (%) ^a	subcohort n=261 (%)	<i>p</i> - value ^b
sex of the child			
male	330 (52.5)	130 (49.8)	0.517
female	299 (47.5)	131 (50.2)	
parental education level ^c			
low	16 (2.5)	3 (1.1)	0.034
intermediate	144 (22.9)	43 (16.5)	
high	469 (74.6)	215 (82.4)	
living & household conditions during pregnancy			
renovation activities			
yes	328 (52.1)	138 (52.9)	0.791
no	278 (44.2)	123 (47.1)	
tobacco smoke exposure ^d			
(almost) daily	48 (7.6)	10 (3.8)	0.101
occasionally	47 (7.5)	18 (6.9)	
never	534 (84.9)	233 (89.3)	
cat ownership			
yes	95 (81.2)	33 (12.6)	0.294
no	511 (15.1)	228 (87.4)	
prevalence of atopic dermatitis			
	n/N (%)	n/N (%)	
maternal history of atopic dermatitis	112/623 (18.0)	50/261 (19.2)	0.750
children's atopic dermatitis phenotypes			
very early-onset AD with remission	14/351 (4.0)	12/261 (4.6)	0.899
very early-onset AD without remission	35/351 (10.0)	32/261 (12.3)	
early-onset AD	42/351 (12.0)	31/261 (11.9)	
childhood-onset AD	10/351 (2.8)	8/261 (3.1)	
maternal chemical exposure			
	median (IQR)	median (IQR)	<i>p</i> -

(urine concentration at gestational week 34)			value ^e
	n=613	n=261	
cotinine [µg/g creatinine]	2.05 (0.78-5.62)	1.92 (0.89-5.04)	0.474
	n=497	n=261	
creatinine [g/l]	0.71 (0.51-1.05)	0.72 (0.53-1.01)	0.750
MeP[µg/l]	39.2 (11.05-156.70)	38.2 (10.80-147.00)	0.822
EtP[µg/l]	2.32 (0.62-13.00)	2.50 (0.75-11.52)	0.865
nPrP[µg/l]	5.00 (1.00-21.50)	4.60 (1.00-21.50)	0.873
iBuP[µg/l]	0.20 (0.05-0.80)	0.17 (0.05-0.75)	0.976
nBuP[µg/l]	0.70 (0.15-3.30)	0.70 (0.16-2.70)	0.803

^anumbers may be different from the total sum due to missing data

^bp-value from chi-squared test for cross-relationship

^clow: nine years of schooling or less (“Hauptschulabschluss”), intermediate: 10 years of schooling (“Mittlere Reife”), high: 12 years of schooling or more (“(Fach-)hochschulreife”)

^danswers based on the question “Did you or anybody else smoke inside your home during the last 12 months?”

^ep-value from Mann-Whitney U-test

Table 2: Association between prenatal paraben exposure and the risk for the development of different AD subtypes. Multinomial logistic regression model. Z-scores of paraben concentrations were used for analysis.

A)

paraben	very early-onset AD with remission (n=178/12)		very early-onset AD without remission (n=178/32)		early-onset AD (n=178/31)		childhood-onset AD (n=178/8)	
	adj.OR ^a (95% CI)	p-value	adj.OR ^a (95% CI)	p-value	adj.OR ^a (95% CI)	p-value	adj.OR ^a (95% CI)	p-value
MeP	0.90 (0.34,2.38)	0.839	1.28 (0.90,1.83)	0.174	1.15 (0.83,1.60)	0.407	0.64 (0.14,2.98)	0.566
EtP	0.82 (0.34,1.99)	0.655	1.44 (1.04,2.00)	0.029	1.06 (0.72,1.55)	0.784	0.31 (0.04,2.50)	0.269
nPrP	1.11 (0.65,1.89)	0.711	1.04 (0.69,1.56)	0.856	1.17 (0.86,1.58)	0.315	0.50 (0.05,4.74)	0.548
iBuP	0.28 (0.01,5.45)	0.401	1.39 (0.99,1.93)	0.054	1.16 (0.83,1.62)	0.380	0.90 (0.32,2.55)	0.840
nBuP	0.23 (0.01,4.63)	0.338	1.95 (1.22,3.12)	0.005	1.55 (0.99,2.43)	0.058	0.72 (0.14,3.75)	0.692

^aOR from multinomial regression adjusted for the child's sex, renovation activities during pregnancy, prenatal tobacco smoke exposure, maternal history of AD, and creatinine concentration at gestational week 34

B) Full adjusted multinomial logistic regression model for very early-onset AD without remission as the dependent variable.

independent variable	EtP		nBuP	
	adj.OR ^a (95% CI)	p-value	adj.OR ^a (95% CI)	p-value
maternal history of AD	3.50 (1.46,8.39)	0.005	4.10 (1.68,10.0)	0.002
prenatal EtP exposure	1.44 (1.04,2.00)	0.029	NA	NA
prenatal nBuP exposure	NA	NA	1.95 (1.22,3.12)	0.005
renovation activities	2.64 (1.12,6.24)	0.027	3.17 (1.29,7.80)	0.012

prenatal tobacco smoke exposure	1.32 (1.00,1.75)	0.052	1.36 (1.02,1.80)	0.035
child's sex	0.89 (0.40,1.99)	0.785	1.01 (0.45,2.30)	0.976

Table 3: Moderation analysis evaluating the moderation effect of a maternal history of AD on the relationship between a prenatal EtP or nBuP exposure and very early-onset AD without remission(n=178 vs. 32).

A) Moderation analysis for EtP and very early-onset AD without remission.

	<i>b</i> coefficient (95% CI)	SE (<i>b</i>)	Z-value	<i>p</i>-value
prenatal EtPexposure ^a	1.03 (0.02,2.05)	0.52	2.00	0.045
history of maternal AD	4.47 (1.62,7.32)	1.46	3.07	0.002
maternal AD x EtP exposure (interaction)	-2.10 (-3.91,-0.29)	0.92	-2.28	0.023
covariates				
child's sex	-0.16 (-0.97,0.65)	0.41	-0.39	0.693
renovation activities	0.95 (0.08,1.82)	0.44	2.15	0.032
prenatal tobacco smoke exposure	0.23 (-0.05,0.52)	0.15	1.62	0.106
conditional effect moderated by maternal AD				
no history of maternal AD	1.03 (0.02,2.05)	0.52	2.00	0.045
history of maternal AD	-1.07 (-2.56,0.43)	0.76	-1.40	0.163

^ahigh/lowEtP prenatal exposure (>/< geometric mean of urinary EtP concentration within the subcohort)

B) Moderation analysis for nBuP and very early-onset AD without remission.

	<i>b</i> coefficient (95% CI)	SE (<i>b</i>)	Z-value	<i>p</i>-value
prenatal nBuPexposure ^a	1.19 (0.14,2.24)	0.54	2.21	0.027
history of maternal AD	3.89 (1.07,6.72)	1.44	2.70	0.007
maternal AD x nBuP exposure (interaction)	-1.68 (-3.47,0.10)	0.91	-1.85	0.065
covariates				
child's sex	-0.09 (-0.90,0.72)	0.41	-0.21	0.831
renovation activities	0.85 (0.00,1.71)	0.44	1.95	0.051
prenatal tobacco smoke exposure	0.25 (-0.05,0.54)	0.15	1.64	0.102
conditional effect moderated by maternal AD				
no history of maternal AD	1.19 (0.14,2.24)	0.54	2.21	0.027
history of maternal AD	-0.49 (-1.98,0.99)	0.76	-0.65	0.514

^ahigh/lownBuP prenatal exposure (>/< geometric mean of urinary nBuP concentration within the subcohort)

References

- 1 Halla, N. *et al.* Cosmetics Preservation: A Review on Present Strategies. *Molecules***23**, doi:10.3390/molecules23071571 (2018).
- 2 Soni, M. G., Carabin, I. G. & Burdock, G. A. Safety assessment of esters of p-hydroxybenzoic acid (parabens). *Food Chem Toxicol***43**, 985-1015, doi:10.1016/j.fct.2005.01.020 (2005).
- 3 Haman, C., Dauchy, X., Rosin, C. & Munoz, J. F. Occurrence, fate and behavior of parabens in aquatic environments: a review. *Water Res***68**, 1-11, doi:10.1016/j.watres.2014.09.030 (2015).
- 4 Bledzka, D., Gromadzinska, J. & Wasowicz, W. Parabens. From environmental studies to human health. *Environ Int***67**, 27-42, doi:10.1016/j.envint.2014.02.007 (2014).
- 5 Dewalque, L., Pirard, C. & Charlier, C. Measurement of urinary biomarkers of parabens, benzophenone-3, and phthalates in a Belgian population. *Biomed Res Int***2014**, 649314, doi:10.1155/2014/649314 (2014).
- 6 Calafat, A. M., Ye, X., Wong, L. Y., Bishop, A. M. & Needham, L. L. Urinary concentrations of four parabens in the U.S. population: NHANES 2005-2006. *Environ Health Perspect***118**, 679-685, doi:10.1289/ehp.0901560 (2010).
- 7 Frederiksen, H. *et al.* Human urinary excretion of non-persistent environmental chemicals: an overview of Danish data collected between 2006 and 2012. *Reproduction***147**, 555-565, doi:10.1530/REP-13-0522 (2014).
- 8 Artacho-Cordon, F. *et al.* Adipose tissue concentrations of non-persistent environmental phenols and local redox balance in adults from Southern Spain. *Environ Int***133**, 105118, doi:10.1016/j.envint.2019.105118 (2019).
- 9 Nowak, K., Ratajczak-Wrona, W., Gorska, M. & Jablonska, E. Parabens and their effects on the endocrine system. *Mol Cell Endocrinol***474**, 238-251, doi:10.1016/j.mce.2018.03.014 (2018).
- 10 Nishihama, Y. *et al.* Association between paraben exposure and menstrual cycle in female university students in Japan. *Reprod Toxicol***63**, 107-113, doi:10.1016/j.reprotox.2016.05.010 (2016).
- 11 Leppert, B. *et al.* Maternal paraben exposure triggers childhood overweight development. *Nat Commun***11**, 561, doi:10.1038/s41467-019-14202-1 (2020).
- 12 Hu, P. *et al.* Differential effects on adiposity and serum marker of bone formation by post-weaning exposure to methylparaben and butylparaben. *Environ Sci Pollut Res Int***23**, 21957-21968, doi:10.1007/s11356-016-7452-0 (2016).

- 13 Nowak, K., Jablonska, E. & Ratajczak-Wrona, W. Immunomodulatory effects of synthetic
endocrine disrupting chemicals on the development and functions of human immune cells.
*Environ Int***125**, 350-364, doi:10.1016/j.envint.2019.01.078 (2019).
- 14 Bredin, J., Davin-Regli, A. & Pages, J. M. Propyl paraben induces potassium efflux in *Escherichia*
coli. *J Antimicrob Chemother***55**, 1013-1015, doi:10.1093/jac/dki110 (2005).
- 15 Hu, J. *et al.* Effect of postnatal low-dose exposure to environmental chemicals on the gut
microbiome in a rodent model. *Microbiome***4**, 26, doi:10.1186/s40168-016-0173-2 (2016).
- 16 Jackson-Browne, M. S., Henderson, N., Patti, M., Spanier, A. & Braun, J. M. The Impact of Early-
Life Exposure to Antimicrobials on Asthma and Eczema Risk in Children. *Curr Environ Health Rep***6**,
214-224, doi:10.1007/s40572-019-00256-2 (2019).
- 17 Savage, J. H., Matsui, E. C., Wood, R. A. & Keet, C. A. Urinary levels of triclosan and parabens are
associated with aeroallergen and food sensitization. *J Allergy Clin Immunol***130**, 453-460 e457,
doi:10.1016/j.jaci.2012.05.006 (2012).
- 18 Spanier, A. J., Fausnight, T., Camacho, T. F. & Braun, J. M. The associations of triclosan and
paraben exposure with allergen sensitization and wheeze in children. *Allergy Asthma Proc***35**, 475-
481, doi:10.2500/aap.2014.35.3803 (2014).
- 19 Quiros-Alcala, L., Hansel, N. N., McCormack, M. C. & Matsui, E. C. Paraben exposures and asthma-
related outcomes among children from the US general population. *J Allergy Clin Immunol***143**,
948-956 e944, doi:10.1016/j.jaci.2018.08.021 (2019).
- 20 Mitsui-Iwama, M. *et al.* Exposure to paraben and triclosan and allergic diseases in Tokyo: A pilot
cross-sectional study. *Asia Pac Allergy***9**, e5, doi:10.5415/apallergy.2019.9.e5 (2019).
- 21 Kolatorova, L., Duskova, M., Vitku, J. & Starka, L. Prenatal exposure to bisphenols and parabens
and impacts on human physiology. *Physiol Res***66**, S305-S315 (2017).
- 22 Lee-Sarwar, K. *et al.* Prenatal and early-life triclosan and paraben exposure and allergic outcomes.
*J Allergy Clin Immunol***142**, 269-278 e215, doi:10.1016/j.jaci.2017.09.029 (2018).
- 23 Vernet, C. *et al.* In Utero Exposure to Select Phenols and Phthalates and Respiratory Health in
Five-Year-Old Boys: A Prospective Study. *Environ Health Perspect***125**, 097006,
doi:10.1289/EHP1015 (2017).
- 24 Berger, K. *et al.* Associations between prenatal maternal urinary concentrations of personal care
product chemical biomarkers and childhood respiratory and allergic outcomes in the CHAMACOS
study. *Environ Int***121**, 538-549, doi:10.1016/j.envint.2018.09.027 (2018).

- 25 Lowe, A. J. *et al.* Exposure to breast milk triclosan and parabens and eczema phenotypes at 12
months: A nested case-control study. *J Allergy Clin Immunol***144**, 1136-1138 e1136,
doi:10.1016/j.jaci.2019.07.001 (2019).
- 26 Bieber, T. Atopic dermatitis 2.0: from the clinical phenotype to the molecular taxonomy and
stratified medicine. *Allergy***67**, 1475-1482, doi:10.1111/all.12049 (2012).
- 27 Schlittenbauer, L., Seiwert, B. & Reemtsma, T. Ultrasound-assisted hydrolysis of conjugated
parabens in human urine and their determination by UPLC-MS/MS and UPLC-HRMS. *Anal Bioanal
Chem***408**, 1573-1583, doi:10.1007/s00216-015-9265-2 (2016).
- 28 Bieber, T. *et al.* Clinical phenotypes and endophenotypes of atopic dermatitis: Where are we, and
where should we go? *J Allergy Clin Immunol***139**, S58-S64, doi:10.1016/j.jaci.2017.01.008 (2017).
- 29 Wen, H. J. *et al.* Predicting risk for early infantile atopic dermatitis by hereditary and
environmental factors. *Br J Dermatol***161**, 1166-1172, doi:10.1111/j.1365-2133.2009.09412.x
(2009).
- 30 Xu, F. *et al.* Residential Risk Factors for Atopic Dermatitis in 3- to 6-Year Old Children: A Cross-
Sectional Study in Shanghai, China. *Int J Environ Res Public Health***13**, doi:10.3390/ijerph13060537
(2016).
- 31 Schuttelaar, M. L. *et al.* Filaggrin mutations in the onset of eczema, sensitization, asthma, hay
fever and the interaction with cat exposure. *Allergy***64**, 1758-1765, doi:10.1111/j.1398-
9995.2009.02080.x (2009).
- 32 Bisgaard, H. *et al.* Risk analysis of early childhood eczema. *J Allergy Clin Immunol***123**, 1355-1360
e1355, doi:10.1016/j.jaci.2009.03.046 (2009).
- 33 Herberth, G. *et al.* Maternal immune status in pregnancy is related to offspring's immune
responses and atopy risk. *Allergy***66**, 1065-1074, doi:10.1111/j.1398-9995.2011.02587.x (2011).
- 34 Bauer, T. *et al.* Environment-induced epigenetic reprogramming in genomic regulatory elements
in smoking mothers and their children. *Mol Syst Biol***12**, 861, doi:10.15252/msb.20156520 (2016).
- 35 Barr, D. B. *et al.* Urinary creatinine concentrations in the U.S. population: implications for urinary
biologic monitoring measurements. *Environ Health Perspect***113**, 192-200, doi:10.1289/ehp.7337
(2005).
- 36 Hayes, A. F. *Introduction to Mediation, Moderation, and Conditional Process Analysis: A
Regression-Based Approach. 2nd ed.* (Guilford Press, 2018).
- 37 Althouse, A. D. Adjust for Multiple Comparisons? It's Not That Simple. *Ann Thorac Surg***101**, 1644-
1645, doi:10.1016/j.athoracsur.2015.11.024 (2016).

- 38 Bonamonte, D. *et al.* The Role of the Environmental Risk Factors in the Pathogenesis and Clinical
Outcome of Atopic Dermatitis. *Biomed Res Int***2019**, 2450605, doi:10.1155/2019/2450605 (2019).
- 39 Stiemsma, L. T. & Michels, K. B. The Role of the Microbiome in the Developmental Origins of
Health and Disease. *Pediatrics***141**, doi:10.1542/peds.2017-2437 (2018).
- 40 Towers, C. V. *et al.* Transplacental passage of antimicrobial paraben preservatives. *J Expo Sci
Environ Epidemiol***25**, 604-607, doi:10.1038/jes.2015.27 (2015).
- 41 Frederiksen, H., Taxvig, C., Hass, U., Vinggaard, A. M. & Nellemann, C. Higher levels of ethyl
paraben and butyl paraben in rat amniotic fluid than in maternal plasma after subcutaneous
administration. *Toxicol Sci***106**, 376-383, doi:10.1093/toxsci/kfn171 (2008).
- 42 Park, N. Y. *et al.* Parabens in breast milk and possible sources of exposure among lactating women
in Korea. *Environ Pollut***255**, 113142, doi:10.1016/j.envpol.2019.113142 (2019).
- 43 Rodriguez-Gomez, R. *et al.* New method for the determination of parabens and bisphenol A in
human milk samples using ultrasound-assisted extraction and clean-up with dispersive sorbents
prior to UHPLC-MS/MS analysis. *J Chromatogr B Analyt Technol Biomed Life Sci***992**, 47-55,
doi:10.1016/j.jchromb.2015.04.022 (2015).
- 44 Grecco, C. F., Souza, I. D. & Queiroz, M. E. C. Recent development of chromatographic methods to
determine parabens in breast milk samples: A review. *J Chromatogr B Analyt Technol Biomed Life
Sci***1093-1094**, 82-90, doi:10.1016/j.jchromb.2018.06.059 (2018).
- 45 Grecco, C., Souza, I., Acquaro Junior, V. & Queiroz, M. Determination of Parabens in Breast Milk
Samples by Dispersive Liquid-Liquid Microextraction (DLLME) and Ultra-High-Performance Liquid
Chromatography Tandem Mass Spectrometry. *Journal of the Brazilian Chemical Society*,
doi:10.21577/0103-5053.20180151 (2018).
- 46 Fisher, M. *et al.* Paraben Concentrations in Maternal Urine and Breast Milk and Its Association
with Personal Care Product Use. *Environ Sci Technol***51**, 4009-4017, doi:10.1021/acs.est.6b04302
(2017).
- 47 Ishiwatari, S. *et al.* Effects of methyl paraben on skin keratinocytes. *J Appl Toxicol***27**, 1-9,
doi:10.1002/jat.1176 (2007).
- 48 Jepsen, A. A. *et al.* High breast milk IL-1 β level is associated with reduced risk of childhood
eczema. *Clinical and experimental allergy : journal of the British Society for Allergy and Clinical
Immunology***46**, 1344-1354, doi:10.1111/cea.12770 (2016).
- 49 Aung, M. T. *et al.* Associations between maternal plasma measurements of inflammatory markers
and urinary levels of phenols and parabens during pregnancy: A repeated measures study. *Sci
Total Environ***650**, 1131-1140, doi:10.1016/j.scitotenv.2018.08.356 (2019).

- 50 Okubo, T., Yokoyama, Y., Kano, K. & Kano, I. ER-dependent estrogenic activity of parabens
assessed by proliferation of human breast cancer MCF-7 cells and expression of ERalpha and PR.
*Food Chem Toxicol***39**, 1225-1232, doi:10.1016/s0278-6915(01)00073-4 (2001).
- 51 Vo, T. T., Yoo, Y. M., Choi, K. C. & Jeung, E. B. Potential estrogenic effect(s) of parabens at the
prepubertal stage of a postnatal female rat model. *Reprod Toxicol***29**, 306-316,
doi:10.1016/j.reprotox.2010.01.013 (2010).
- 52 Sun, L. *et al.* The estrogenicity of methylparaben and ethylparaben at doses close to the
acceptable daily intake in immature Sprague-Dawley rats. *Sci Rep***6**, 25173,
doi:10.1038/srep25173 (2016).
- 53 ECHA, c. Substance Information on Butyl 4-hydroxybenzoate accessed: 08 February 2021.
<https://www.echa.europa.eu/web/guest/substance-information/-/substanceinfo/100.002.108>.
- 54 Hu, C. *et al.* Eczema phenotypes and risk of allergic and respiratory conditions in school age
children. *Clin Transl Allergy***10**, 7, doi:10.1186/s13601-020-0310-7 (2020).
- 55 Scientific Committee on Consumer Safety, S. O. SCCS (Scientific Committee on Consumer Safety):
Clarification on Opinion SCCS/1348/10 in the light of the Danish clause of safeguard banning the
use of parabens in cosmetic products intended for children under three years of age, 10 October
2011. (2011).
- 56 ECHA, d. Substance Information on Ethyl 4-hydroxybenzoate accessed: 08 February 2021.
<https://www.echa.europa.eu/web/guest/substance-information/-/substanceinfo/100.004.000>.
- 57 (SCCS), S. C. o. C. S. Opinion on Parabens_Updated request for a scientific opinion on propyl- and
butylparaben. Accessed 08 February 2021.
https://ec.europa.eu/health/scientific_committees/consumer_safety/docs/sccs_o_132.pdf.
(2013).

Figures

Figure 1: Overview of the analyzed AD subtypes and the LINA subcohort. (A) Classification of AD phenotypes according to age at disease onset and disease persistence based on Bieber *et al.* 2017. (B) Flow chart illustrating the selection of participants enrolled in the LINA study, which were included in this study. Only children with a valid maternal paraben measurement and longitudinal information on AD outcome and covariates were considered for this analysis.

Figure 2: Directed acyclic graph depicts the hypothesized relationship between prenatal paraben exposure and atopic dermatitis and shows the potential confounders classified in genetic factors and lifestyle factors during pregnancy (black arrows). As the parental education level was significantly associated with smoking and renovation during pregnancy, it was omitted as a covariate (blue arrows).

Figure 3: Maternal urinary EtP and nBuP concentration according to children's AD subtypes (mean $\pm$ SEM). *p*-value from multinomial logistic regression adjusted for the child's sex, maternal AD history, renovation activities during pregnancy, prenatal tobacco smoke exposure, and creatinine concentration at gestational week 34.

Figure 4: Impact of the maternal history of AD on the relationship between prenatal EtP or nBuP exposure and the risk for very early-onset AD without remission. The graphical illustration shows moderating effect of the child's history of maternal AD on the association between a prenatal (A) EtP or (B) nBuP exposure and the development of very early-onset AD without remission. # *b* interaction coefficient between EtP or nBuP and the history of maternal AD from moderation model adjusted for the child's sex, renovation activities during pregnancy, prenatal tobacco smoke exposure, and creatinine concentration at gestational week 34. For details, refer to Table 3.





Figure 1

**Figure 2**

control
very early-onset AD
without remission
very early-onset AD
with remission
early-onset AD
childhood-onset AD




Figure 4




Figure S1




Figure S2

Supplemental Material

Prenatal paraben exposure and atopic dermatitis-related outcomes among children

Loreen Thürmann, PhD^{a†}, Gunda Herberth, PhD^{b†}, Bettina Seiwert, PhD^{†c}, Linda Schlittenbauer, PhD^c, Ulrike Rolle-Kampczyk, PhD^d, Stefan Röder, PhD^b, Ulrich Sack, MD^e, Michael Borte, MD^f, Martin von Bergen, PhD^{d,g}, Saskia Trump, PhD^{a†}, Thorsten Reemtsma, PhD^{c†}, Irina Lehmann, PhD^{a*†}

- ^a Molecular Epidemiology Unit, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, associated partner of the German Center for Lung Research (DZL), Berlin, Germany
- ^b Department of Environmental Immunology, Helmholtz Centre for Environmental Research-UFZ, Leipzig, Germany
- ^c Department of Analytical Chemistry, Helmholtz Centre for Environmental Research – UFZ, Leipzig, Germany
- ^d Department of Molecular Systems Biology, Helmholtz-Centre for Environmental Research-UFZ, Leipzig, Germany
- ^e Institute of Clinical Immunology, Medical Faculty, University Leipzig, Leipzig, Germany.
- ^f Children's Hospital, Municipal Hospital "St.Georg", Academic Teaching Hospital of the University of Leipzig, Leipzig, Germany
- ^g Department of Biochemistry, Faculty of Biosciences, Pharmacy and Psychology, University of Leipzig, Leipzig, Germany

† equal contribution

*Corresponding author:

Prof. Dr. Irina Lehmann, Molecular Epidemiology Unit, Charité - Universitätsmedizin Berlin and Berlin Institute of Health, Kapelle-Ufer 2, 10117 Berlin, Phone: +4930-450-543094, Fax: +4930-450-7-576902, mail: irina.lehmann@charite.de

Table S1: Characteristics of urinary paraben concentration at gestational week 34 (n=261).

paraben	mean [$\mu\text{g/l}$]	median [$\mu\text{g/l}$]	min/max [$\mu\text{g/l}$]	SD (95% CI) [$\mu\text{g/l}$]	number of samples <LOQ n (%)
MeP	149.9	38.2	0.3/3680	348.5 (321,381.3)	1 (0.4)
EtP	15.5	2.5	0.1/269	33.2 (30.6,36.4)	9 (3.4)
iPrP	0.5	0.1	0.1/40.8	3.6 (3.3,4.0)	236 (90.4)
nPrP	32.0	4.6	0.1/1060	98.7 (90.9,108.0)	6 (2.3)
sBuP	n.a.	n.a.	n.a.	n.a.	261 (100)
iBuP	1.7	0.2	0.1/46.4	5.6 (5.1,6.1)	90 (34.5)
nBuP	6.3	0.7	0.1/269	21.2 (19.5,23.2)	48 (18.4)
BzP	0.1	0.1	0.1/0.6	0.1 (0.0,0.1)	232 (88.9)

LOQ = limit of quantification

Table S2: Spearman's rank-order correlation between maternal urine paraben concentrations [$\mu\text{g/l}$]. Indicated are the correlation coefficient R and *p*-value.

	MeP	EtP	nPrP	iBuP	nBuP
MeP		0.71 <i>p</i> <0.0001	0.84 <i>p</i> <0.0001	0.46 <i>p</i> <0.0001	0.56 <i>p</i> <0.0001
EtP	0.71 <i>p</i> <0.0001		0.67 <i>p</i> <0.0001	0.59 <i>p</i> <0.0001	0.69 <i>p</i> <0.0001
nPrP	0.84 <i>p</i> <0.0001	0.67 <i>p</i> <0.0001		0.45 <i>p</i> <0.0001	0.49 <i>p</i> <0.0001
iBuP	0.46 <i>p</i> <0.0001	0.59 <i>p</i> <0.0001	0.45 <i>p</i> <0.0001		0.79 <i>p</i> <0.0001
nBuP	0.56 <i>p</i> <0.0001	0.69 <i>p</i> <0.0001	0.49 <i>p</i> <0.0001	0.79 <i>p</i> <0.0001	

Table S3: Association between prenatal paraben exposure and the risk for the development of different AD subtypes – crude multinomial logistic regression models. Z-scores of paraben concentrations were used for analyses.

paraben	very early-onset AD with remission (n=178/12)		very early-onset AD without remission (n=178/32)		early-onset AD (n=178/31)		childhood-onset AD (n=178/8)	
	OR (95% CI)	<i>p</i> - value	OR (95% CI)	<i>p</i> - value	OR (95% CI)	<i>p</i> - value	OR (95% CI)	<i>p</i> - value
MeP	0.86 (0.34,2.19)	0.749	1.18 (0.86,1.60)	0.302	1.16 (0.84,1.60)	0.361	0.80 (0.22,2.89)	0.731
EtP	0.87 (0.39,1.93)	0.729	1.30 (0.97,1.75)	0.080	1.08 (0.74,1.58)	0.695	0.41 (0.05,3.52)	0.418
nPrP	1.07 (0.63,1.81)	0.811	1.00 (0.66,1.53)	0.995	1.16 (0.88,1.54)	0.296	0.63 (0.08,4.67)	0.651
iBuP	0.34 (0.02,5.66)	0.455	1.21 (0.90,1.63)	0.212	1.17 (0.85,1.61)	0.337	0.99 (0.42,2.34)	0.977
nBuP	0.32 (0.02,5.79)	0.441	1.60 (1.06,2.42)	0.026	1.47 (0.96,2.26)	0.076	1.00 (0.26,3.80)	0.999

Table S4: Contribution of prenatal EtP or nBuP exposure on the risk to develop very early-onset AD without remission separately for children with or without a history of maternal AD. Paraben concentration was ln-transformed before analysis by binary logistic regression.

paraben	model	NO history of maternal AD (n=20 vs. 149)		history of maternal AD (n=12 vs. 29)	
		OR (95% CI)	p-value	OR (95% CI)	p-value
EtP	crude	1.36 (1.06,1.76)	0.017	1.05 (0.76,1.44)	0.785
	adjusted ^a	1.43 (1.09,1.89)	0.010	1.05 (0.70,1.57)	0.797
nBuP	crude	1.28 (1.02,1.60)	0.034	0.94 (0.66,1.33)	0.721
	adjusted ^a	1.37 (1.06,1.78)	0.016	1.07 (0.69,1.64)	0.759

^alogistic regression adjusted for the child's sex, renovation activities during pregnancy, prenatal tobacco smoke exposure, and creatinine concentration at gestational week 34

Table S5: Contribution of prenatal EtP and nBuP exposure to the risk to develop very early-onset AD separately for girls and boys. Paraben concentration was ln-transformed before analysis.

paraben	model	boys (n=85 vs. 16)		girls (n=93 vs. 16)	
		OR (95% CI)	<i>p</i> -value	OR (95% CI)	<i>p</i> -value
EtP	crude	1.11 (0.85,1.45)	0.427	1.40 (1.04,1.89)	0.026
	adjusted ^a	1.20 (0.89,1.61)	0.219	1.47 (1.06,2.03)	0.018
nBuP	crude	1.19 (0.93,1.53)	0.173	1.13 (0.86,1.49)	0.377
	adjusted ^a	1.30 (0.97,1.72)	0.071	1.30 (0.93,1.82)	0.119

^alogistic regression adjusted for renovation activities during pregnancy, prenatal tobacco smoke exposure, maternal history of AD, and creatinine concentration at gestational week 34

Supplementary Table S6: Moderation analysis evaluating the moderating effect of child's sex on the relationship between a prenatal EtP or nBuP exposure and very early-onset AD without remission (n=178 vs. 32).

A) Moderation analysis for EtP and very early-onset AD without remission.

	b coefficient (95% CI)	SE (b)	Z-value	p-value
prenatal EtP exposure ^a	-0.97 (-3.5,1.57)	1.29	-0.75	0.456
child's sex	-1.51 (-4.08,1.06)	1.31	-1.15	0.249
child's sex x EtP exposure (interaction)	0.89 (-0.72,2.5)	0.82	1.09	0.278
covariates				
history of maternal AD	1.28 (0.41,2.15)	0.44	2.88	0.004
renovation activities	0.84 (-0.01,1.69)	0.43	1.94	0.052
prenatal tobacco smoke exposure	0.25 (-0.03,0.52)	0.14	1.74	0.083

^ahigh/low EtP prenatal exposure (>/< geometric mean of urinary EtP concentration within the subcohort)

B) Moderation analysis for nBuP and very early-onset AD without remission.

	b coefficient (95% CI)	SE (b)	Z-value	p-value
prenatal nBuP exposure ^a	0.45 (-2.13,3.04)	1.32	0.34	0.731
child's sex	-0.28 (-2.93,2.37)	1.35	-0.21	0.836
child's sex x nBuP exposure (interaction)	0.13 (-1.49,1.74)	0.83	0.15	0.878
covariates				
history of maternal AD	1.35 (0.48,2.23)	0.45	3.03	0.002
renovation activities	0.92 (0.06,1.78)	0.44	2.1	0.036
prenatal tobacco smoke exposure	0.26 (-0.02,0.55)	0.14	1.83	0.067

^ahigh/low nBuP prenatal exposure (>/< geometric mean of urinary nBuP concentration within the subcohort)

Figures

Supplementary Figure S1: Longitudinal total IgE concentration of children with atopic dermatitis. Significant changes comparing controls with AD are indicated by * p -value<0.05, ** p -value<0.005, and *** p -value<0.0005 derived from Mann-Whitney U-test. The color of the stars represents the comparison of the respective AD subtype to the control group. Shown is median +/- 95% CI.

Supplementary Figure S2: Forest plots depict the association between ln-transformed prenatal EtP or nBuP concentration and the risk for very early-onset AD without remission in distinct subgroups of children. *OR from logistic regression adjusted for the child's sex and/or maternal AD history, renovation activities during pregnancy, prenatal tobacco smoke exposure, and creatinine concentration at gestational week 34.